Market Cap 13.51M
Revenue (ttm) 0.00
Net Income (ttm) -178.01M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin 0.00%
Debt to Equity Ratio 0.00
Volume 30,064
Avg Vol 1,646,707
Day's Range N/A - N/A
Shares Out 4.53M
Stochastic %K 75%
Beta 0.40
Analysts Strong Buy
Price Target N/A

Company Profile

Lunai Bioworks Inc., a pre-clinical stage biotechnology company, provides medicine, diagnostics, and biodefense products the United States and the Netherlands. It operates through three segments, RENB, BioSymetrics, and RENC. The company is developing a genetically modified allogeneic dendritic cell therapeutic vaccines, including RENB-DC11 to treat solid tumors primarily for pancreatic tumors; and RENB-DC20 for the treatment of breast cancer. It also develops an artificial intelligence platform...

Industry: Biotechnology
Sector: Healthcare
Phone: 305 918 1980
Address:
2080 Century Park East, Suite 906, Los Angeles, United States
Porto98
Porto98 Jun. 4 at 4:04 PM
0 · Reply
KaShing01
KaShing01 Jun. 4 at 1:48 PM
$LNAI Added Another 1k shares to these retarded dips.
0 · Reply
supplySHOCK
supplySHOCK Jun. 4 at 10:48 AM
0 · Reply
supplySHOCK
supplySHOCK Jun. 4 at 10:33 AM
0 · Reply
supplySHOCK
supplySHOCK Jun. 4 at 8:21 AM
0 · Reply
Porto98
Porto98 Jun. 2 at 11:15 PM
$LNAI news , real positive news will make this fly… no doubt
0 · Reply
Porto98
Porto98 Jun. 2 at 6:46 PM
0 · Reply
bigbathtime
bigbathtime Jun. 2 at 12:51 PM
$LNAI maybe not 😂
0 · Reply
bigbathtime
bigbathtime Jun. 2 at 12:45 PM
$LNAI is this a real move?
0 · Reply
matthewboyntonbeach
matthewboyntonbeach Jun. 1 at 1:45 PM
$LNAI wont get noticed till $6
0 · Reply
Latest News on LNAI
Lunai Bioworks Inc. trading halted, news pending

2026-05-21T23:50:36.000Z - 13 days ago

Lunai Bioworks Inc. trading halted, news pending


Lunai Bioworks announces reverse stock split

2026-05-20T13:21:05.000Z - 15 days ago

Lunai Bioworks announces reverse stock split


LUNAI BIOWORKS, INC. ANNOUNCES REVERSE STOCK SPLIT

May 20, 2026, 9:15 AM EDT - 15 days ago

LUNAI BIOWORKS, INC. ANNOUNCES REVERSE STOCK SPLIT


Lunai Bioworks Quarterly report: Q3 2026

May 15, 2026, 7:00 AM EDT - 20 days ago

Lunai Bioworks Quarterly report: Q3 2026


Lunai Bioworks Proxy statement: Proxy filing

May 1, 2026, 8:00 AM EDT - 4 weeks ago

Lunai Bioworks Proxy statement: Proxy filing


Lunai Bioworks Proxy statement: Proxy filing

Apr 28, 2026, 8:00 AM EDT - 5 weeks ago

Lunai Bioworks Proxy statement: Proxy filing


Lunai Bioworks Proxy statement: Proxy filing

Apr 15, 2026, 8:00 AM EDT - 7 weeks ago

Lunai Bioworks Proxy statement: Proxy filing


Lunai Bioworks Proxy statement: Proxy filing

Apr 13, 2026, 8:00 AM EDT - 7 weeks ago

Lunai Bioworks Proxy statement: Proxy filing


Lunai Bioworks Proxy statement: Proxy filing

Apr 2, 2026, 8:00 AM EDT - 2 months ago

Lunai Bioworks Proxy statement: Proxy filing


Lunai Bioworks announces formation of Pathfinder Consortium

2026-03-19T14:10:31.000Z - 2 months ago

Lunai Bioworks announces formation of Pathfinder Consortium


Why Is Lunai Bioworks Stock (LNAI) Rallying Today?

2026-03-17T12:29:40.000Z - 2 months ago

Why Is Lunai Bioworks Stock (LNAI) Rallying Today?


Lunai Bioworks granted U.S. patent for AI drug discovery system

2026-02-19T13:47:50.000Z - 3 months ago

Lunai Bioworks granted U.S. patent for AI drug discovery system


Lunai Bioworks Quarterly report: Q2 2026

Feb 17, 2026, 7:00 AM EST - 3 months ago

Lunai Bioworks Quarterly report: Q2 2026


Lunai Bioworks Slides: Investor presentation

Feb 5, 2026, 7:00 AM EST - 4 months ago

Lunai Bioworks Slides: Investor presentation


Lunai Bioworks Quarterly report: Q1 2026

Nov 14, 2025, 7:00 AM EST - 7 months ago

Lunai Bioworks Quarterly report: Q1 2026


Lunai Bioworks announces early results from AI-based platform

2025-10-30T13:41:27.000Z - 7 months ago

Lunai Bioworks announces early results from AI-based platform


Lunai Bioworks Proxy statement: Proxy Filing

Oct 15, 2025, 8:00 AM EDT - 8 months ago

Lunai Bioworks Proxy statement: Proxy Filing


Lunai Bioworks Annual report: Q4 2025

Sep 29, 2025, 4:00 PM EDT - 8 months ago

Lunai Bioworks Annual report: Q4 2025


Lunai Bioworks, Inc. to Effect 10:1 Reverse Stock Split

Sep 24, 2025, 4:50 PM EDT - 9 months ago

Lunai Bioworks, Inc. to Effect 10:1 Reverse Stock Split


Lunai Bioworks Inc. Retains American Defense International

Sep 4, 2025, 10:05 AM EDT - 9 months ago

Lunai Bioworks Inc. Retains American Defense International


Lunai Bioworks Proxy statement: Proxy Filing

Jul 30, 2025, 8:00 AM EDT - 11 months ago

Lunai Bioworks Proxy statement: Proxy Filing


Lunai Bioworks Proxy statement: Proxy Filing

Jul 18, 2025, 8:00 AM EDT - 11 months ago

Lunai Bioworks Proxy statement: Proxy Filing


Lunai Bioworks Quarterly report: Q3 2025

May 15, 2025, 4:00 PM EDT - 1 year ago

Lunai Bioworks Quarterly report: Q3 2025


Renovaro Announces $15 million in Equity Committed

Feb 26, 2025, 9:15 AM EST - 1 year ago

Renovaro Announces $15 million in Equity Committed


Lunai Bioworks Quarterly report: Q2 2025

Feb 19, 2025, 4:00 PM EST - 1 year ago

Lunai Bioworks Quarterly report: Q2 2025


Lunai Bioworks Slides: Investor Presentation

Feb 19, 2025, 11:00 AM EST - 1 year ago

Lunai Bioworks Slides: Investor Presentation


Renovaro Appoints Nathen Fuentes as Chief Financial Officer

Jan 7, 2025, 9:15 AM EST - 1 year ago

Renovaro Appoints Nathen Fuentes as Chief Financial Officer


Porto98
Porto98 Jun. 4 at 4:04 PM
0 · Reply
KaShing01
KaShing01 Jun. 4 at 1:48 PM
$LNAI Added Another 1k shares to these retarded dips.
0 · Reply
supplySHOCK
supplySHOCK Jun. 4 at 10:48 AM
0 · Reply
supplySHOCK
supplySHOCK Jun. 4 at 10:33 AM
0 · Reply
supplySHOCK
supplySHOCK Jun. 4 at 8:21 AM
0 · Reply
Porto98
Porto98 Jun. 2 at 11:15 PM
$LNAI news , real positive news will make this fly… no doubt
0 · Reply
Porto98
Porto98 Jun. 2 at 6:46 PM
0 · Reply
bigbathtime
bigbathtime Jun. 2 at 12:51 PM
$LNAI maybe not 😂
0 · Reply
bigbathtime
bigbathtime Jun. 2 at 12:45 PM
$LNAI is this a real move?
0 · Reply
matthewboyntonbeach
matthewboyntonbeach Jun. 1 at 1:45 PM
$LNAI wont get noticed till $6
0 · Reply
matthewboyntonbeach
matthewboyntonbeach Jun. 1 at 1:00 PM
$LNAI still 2 million shares short, we break $4 today
0 · Reply
BillionaireMotion
BillionaireMotion May. 29 at 5:40 PM
0 · Reply
Porto98
Porto98 May. 29 at 3:42 PM
0 · Reply
Morgan8758
Morgan8758 May. 29 at 1:54 PM
$LNAI Stocktwits seems to not update this specific ticker’s price regularly.
0 · Reply
Stengaard1
Stengaard1 May. 29 at 8:46 AM
$LNAI I have spent some time analysing Fintel.io's dataset for shortselling of Lunai - AND corrected for pre/post-split (which Fintel does not) For those interested - and you should all be :) here's a clean, fairly readable summary based on the FINRA Off-Exchange dataset: $LNAI — Short Selling Analysis Based on FINRA Off-Exchange Data (May 14–28, 2026) What the data shows Over the last 10 trading days, more than half of all LNAI trading activity has consistently been short selling. This isn't a one-day anomaly — it's a sustained pattern across every single day in the dataset. Day by day (split-adjusted where applicable) Before the 1:8 reverse split (May 14–21) — figures divided by 8: DateShort Vol (adj.)Total Vol (adj.)Short %May 1439,59662,59663.26%May 1523,99248,18449.79%May 1832,31372,30344.69%May 1912,70127,19146.71%May 2035,65785,07141.91%May 21117,090163,83471.47% After the 1:8 reverse split (May 22–28) — no adjustment needed: DateShort VolTotal VolShort %May 2252,035119,74843.45%May 2619,72645,81643.05%May 27185,667304,85260.90%May 28147,450239,06461.68% Three things stand out 1. The short ratio never drops below 41% On every single trading day, at least 4 out of every 10 shares traded were short sales. On the worst days it was nearly 7 out of 10. For context, a "normal" short volume ratio for a healthy stock is typically 20–30%. 2. May 21 is the red flag day The day before the reverse split, short volume spiked to over 117,000 split-adjusted shares — nearly 3x any other day — with a 71.47% short ratio. This is the single most suspicious data point, as it suggests a concentrated push to short the stock on the last day before the new CUSIP took effect, potentially to exploit the split transition. 3. Shorting has actually accelerated post-split May 27–28 show the highest raw short volumes in the entire post-split period, with ratios of 60–62%. The reverse split — which was meant to stabilise the stock — does not appear to have deterred the short sellers at all. Bottom line The FINRA data paints a consistent picture of sustained, heavy short selling pressure on a stock with only ~4.5 million shares outstanding. The spike immediately before the reverse split, combined with the company's active lawsuit alleging naked short selling, means this data is unlikely to be coincidental. The pattern warrants serious scrutiny.$LNAI certainly looks to have a case ! Bullish
0 · Reply
Stengaard1
Stengaard1 May. 29 at 8:43 AM
$LNAI Based on the FINRA Off-Exchange dataset, here's the split-adjusted total so all of you numbers-fixated investors have something to read: Pre-split (÷8): DateShort Vol (adj.)May 1439,596May 1523,992May 1832,313May 1912,701May 2035,657May 21117,090Subtotal261,349 Post-split (no adjustment): DateShort VolMay 2252,035May 2619,726May 27185,667May 28147,450Subtotal404,878 Grand Total: 666,227 short-sold shares Against a post-split float of ~4,533,890 shares, that represents 14.7% of the entire float shorted in just 10 trading days. To put that in perspective — at that pace, the equivalent of 100% of the float would be shorted in approximately 68 trading days, or roughly 13 weeks. That is an extraordinarily aggressive short position for any stock, let alone a micro-cap with a Nasdaq compliance deadline looming.
0 · Reply
Stengaard1
Stengaard1 May. 29 at 8:33 AM
$LNAI Fails-to-Deliver happens when a stock seller doesn't actually hand over the shares they sold within the required settlement window. It's tracked and published by the SEC. High FTD numbers can be a red flag — sometimes associated with naked short selling or liquidity problems. What the chart shows: FTDs were relatively quiet from Oct 2025 through Feb 2026 Then a massive spike in April 2026 — peaking around 6–7 million shares failed to deliver It has come down since but remains elevated in May 2026 The table (recent figures): The worst single day visible was around May 5, 2026 with over 3 million FTDs at $0.32/share, and May 7–8 with 675K–736K at $0.31–0.33. Is this concerning for Lunai (LNAI)? Yes, and it's definetely worth watching. The April spike is unusually large relative to the company's size and price (stock trading around $0.30–0.35). Combined with it being a micro-cap penny stock, high FTDs can signal aggressive short selling or settlement issues. It's not proof of wrongdoing, but it's a data point that warrants caution
0 · Reply
matthewboyntonbeach
matthewboyntonbeach May. 28 at 10:15 PM
$LNAI $8.20 looks legit tomorrow
0 · Reply
matthewboyntonbeach
matthewboyntonbeach May. 28 at 5:49 PM
$LNAI $6.60 on deck
1 · Reply
Stengaard1
Stengaard1 May. 28 at 5:47 PM
$LNAI todays announcement - in laymans terms https://www.prnewswire.com/news-releases/lunai-bioworks-and-brainstorm-therapeutics-launch-foundation-funded-parkinsons-and-rare-epilepsy-ai-discovery-collaboration-302784369.html Lunai and BrainStorm Therapeutics are teaming up to use AI to find new treatments for brain diseases. $LNAI and BrainStorm T. announced a partnership focusing on Parkinson's disease and a rare form of epilepsy. Here's what each company brings to the table: BioSymetrics(Lunia) contributes with their AI system that sifts through enormous amounts of biological data to identify promising drug targets, and then, as most of you know, tests findings in zebrafish. BrainStorm T. brings something they call "brain organoids" — (which are essentially tiny, lab-grown clumps of human brain tissue made from human stem cells). These brain organoids act as miniature stand-ins for a real human brain; this will help researchers understand how a disease actually behaves in human tissue. Why this combo is interesting and may matter, you might ask? Traditionally, drugs are tested in mice or rats, which often don't translate well to humans — a major reason so many drugs fail in clinical trials. This collaboration is aligned with new FDA guidance encouraging methods that better reflect human biology and reduce reliance on traditional animal models. By combining AI, human brain organoids, and zebrafish testing, they're trying to build a more reliable pipeline. Are they burning cash? Probably not; a grant from the LouLou Foundation (a foundation focused on rare epilepsy) is helping fund the initial work. I can't see if it is actually cash-flow-positive, but normally the grants cover the expenses plus a little overhead; there is likely additional funding stemming from researchers from Harvard Medical School and Brigham and Women's Hospital, but it is not disclosed The ultimate goal: As I see it, they're not trying to bring a drug to market themselves (at least not initially). The plan is more to identify and validate strong drug candidates, then license or partner with larger pharmaceutical companies to take it further. The collaboration is designed to generate a portfolio of neurology programs that could be advanced through licensing agreements, co-development partnerships, or even new company formation. In short: two small biotech companies are combining AI smarts and cutting-edge lab models to find better brain disease drug targets faster, with the aim to sell or partner those programs to bigger players in pharma. Let's hope it turns out well :)
2 · Reply
matthewboyntonbeach
matthewboyntonbeach May. 28 at 5:43 PM
$LNAI partner company trades on OTC market cap 8 million
1 · Reply
KaShing01
KaShing01 May. 28 at 2:39 PM
$LNAI $5-$8.25+
0 · Reply